Germline Testing In Advanced Cancer Can Lead to Targeted Tx
R Nelson, Medscape, June 2, 2020
R Nelson, Medscape, June 2, 2020
From 7% to nearly 9% of patients with advanced cancer were found to harbor a germline variant with targeted therapeutic actionability in the first study of its kind. The study involved 11,975 patients with various tumor types. All the patients underwent germline genetic testing from 2015 to 2019.
.png)
No hay comentarios:
Publicar un comentario